Drugs / GVAX
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01773395 Comparator | Jan 2013 → Dec 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01773395 ↗ |
| Modality | Vaccine | “GVAX, a vaccine made from the patient's own cancer cells engineered to produce a protein called GM-CSF” NCT01773395 ↗ |
| Route | Subcutaneous | “the GVAX or placebo vaccine will be administered as an injection under and into the skin on the forearms or thighs” NCT01773395 ↗ |